Particulars (Rupees in Crores.) | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 |
---|---|---|---|---|---|
Gross Sales | 166.7 | 132.53 | 163.49 | 147.35 | 115.72 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 166.7 | 132.53 | 163.49 | 147.35 | 115.72 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 16.99 | 36.3 | 6.39 | 7.42 | 6.54 |
Total Income | 183.69 | 168.83 | 169.88 | 154.77 | 122.26 |
Total Expenditure | 167.88 | 159.41 | 155.53 | 140.35 | 129.71 |
PBIDT | 15.81 | 9.42 | 14.35 | 14.42 | -7.45 |
Interest | 0.86 | 1.04 | 0.99 | 0.98 | 0.87 |
PBDT | 14.95 | 8.38 | 13.36 | 13.44 | -8.32 |
Depreciation | 8.39 | 8.42 | 8.98 | 8.68 | 8.73 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0.01 | 0 | 0 | 0 |
Deferred Tax | 2.6 | 1.94 | -0.06 | 0.05 | -1.17 |
Reported Profit After Tax | 3.96 | -1.99 | 4.44 | 4.71 | -15.88 |
Minority Interest After NP | -0.09 | -0.1 | -0.08 | -0.09 | -0.08 |
Net Profit after Minority Interest | 4.05 | -1.89 | 4.52 | 4.8 | -15.8 |
Extra-ordinary Items | 8.72 | 25.76 | 2.77 | 2.74 | 2.74 |
Adjusted Profit After Extra-ordinary item | -4.67 | -27.65 | 1.75 | 2.06 | -18.54 |
EPS (Unit Curr.) | 0.66 | -0.31 | 0.74 | 0.77 | -2.59 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 9.48 | 7.1 | 8.77 | 9.78 | -6.43 |
PBDTM(%) | 8.96 | 6.32 | 8.17 | 9.12 | -7.18 |
PATM(%) | 2.37 | -1.5 | 2.71 | 3.19 | -13.72 |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.